Every material Form 8-K DIVERSIFIED HEALTHCARE TRUST has filed with the SEC since June 01, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Diversified Healthcare Trust reported a third quarter 2026 net loss of $50.2 million, or $0.21 per share, compared with a net loss of $164.0 million, or $0.68 per share, a year earlier. Total revenues fell to $367.7 million from $388.7 million, while Normalized FFO rose to $30.7 million, or $0.13 per share. The company lowered its full year 2026 Normalized FFO per share guidance to $0.46 to $0.52 from $0.56 to $0.62, and said the updated figures now include an estimated $29.3 million incentive management fee.
Q3 2026 net loss was $50.2 million, or $0.21 per share, versus $164.0 million, or $0.68 per share, in Q3 2025.
Total revenues were $367.7 million, down from $388.7 million a year earlier; Normalized FFO was $30.7 million, or $0.13 per share, versus $0.02 per share a year earlier.
Updated 2026 Normalized FFO per share guidance is $0.46 to $0.52, down from $0.56 to $0.62; Adjusted EBITDAre guidance is $275.7 million to $290.7 million, down from $300.0 million to $315.0 million.
Guidance now includes an estimated 2026 incentive management fee of $29.3 million, or $0.12 per share, which the company previously excluded.
Diversified Healthcare Trust reported a second quarter 2026 net loss of $37.4 million, or $0.16 per share, compared with a net loss of $91.6 million, or $0.38 per share, a year earlier. Revenue fell to $365.4 million from $382.7 million, while normalized FFO rose to $38.9 million, and the company said its updated full year 2026 guidance is consistent with its June 1, 2026 release.
Net loss was $37.4 million, or $0.16 per share, for the quarter ended June 30, 2026, versus $91.6 million, or $0.38 per share, a year earlier.
Total revenues were $365.4 million, down from $382.7 million in the second quarter of 2025.
Normalized FFO was $38.9 million, or $0.16 per share, up 109.4% year over year.
Full year 2026 normalized FFO guidance is $135 million to $150 million, consistent with the June 1, 2026 release.
Diversified Healthcare Trust posted an investor presentation on June 1, 2026 that raises its full-year 2026 guidance. Normalized FFO per common share is now expected at $0.56 to $0.62, up from $0.52 to $0.58, and the company attributes the $10 million midpoint increase in SHOP NOI to expense savings in dietary and labor costs.
Normalized FFO per common share guidance rose to $0.56-$0.62 from $0.52-$0.58, a $0.04 increase at the midpoint.
Normalized FFO guidance is $135 million-$150 million, up from $125 million-$140 million; Adjusted EBITDAre guidance is $300 million-$315 million, up from $290 million-$305 million.
SHOP NOI guidance rose to $185 million-$195 million from $175 million-$185 million, driven by targeted cost initiatives, primarily across dietary and labor.
Moody's upgraded the company to B3 in April 2026 and revised its ratings outlook from stable to positive.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every DIVERSIFIED HEALTHCARE TRUST filing is on SEC EDGAR ↗. 8-K briefs of other companies →